88 related articles for article (PubMed ID: 16914585)
1. Successful radiotherapy of tumor in pretargeted mice by 188Re-radiolabeled phosphorodiamidate morpholino oligomer, a synthetic DNA analogue.
Liu G; Dou S; Mardirossian G; He J; Zhang S; Liu X; Rusckowski M; Hnatowich DJ
Clin Cancer Res; 2006 Aug; 12(16):4958-64. PubMed ID: 16914585
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Applications of Pretargeting.
Verhoeven M; Seimbille Y; Dalm SU
Pharmaceutics; 2019 Sep; 11(9):. PubMed ID: 31480515
[TBL] [Abstract][Full Text] [Related]
3. A Revisit to the Pretargeting Concept-A Target Conversion.
Liu G
Front Pharmacol; 2018; 9():1476. PubMed ID: 30618765
[TBL] [Abstract][Full Text] [Related]
4. Drug-Free Macromolecular Therapeutics--A New Paradigm in Polymeric Nanomedicines.
Chu TW; Kopeček J
Biomater Sci; 2015 Jul; 3(7):908-22. PubMed ID: 26191406
[TBL] [Abstract][Full Text] [Related]
5. Quantitative Correlation of in Vivo Properties with in Vitro Assay Results: The in Vitro Binding of a Biotin-DNA Analogue Modifier with Streptavidin Predicts the in Vivo Avidin-Induced Clearability of the Analogue-Modified Antibody.
Dou S; Virostko J; Greiner DL; Powers AC; Liu G
Mol Pharm; 2015 Aug; 12(8):3097-103. PubMed ID: 26103429
[TBL] [Abstract][Full Text] [Related]
6. Pushing the envelope-nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation.
Pingali SR; Champlin RE
Bone Marrow Transplant; 2015 Sep; 50(9):1157-67. PubMed ID: 25985053
[TBL] [Abstract][Full Text] [Related]
7. A feasible approach to evaluate the relative reactivity of NHS-ester activated group with primary amine-derivatized DNA analogue and non-derivatized impurity.
Dou S; Virostko J; Greiner DL; Powers AC; Liu G
Nucleosides Nucleotides Nucleic Acids; 2015; 34(2):69-78. PubMed ID: 25621701
[TBL] [Abstract][Full Text] [Related]
8. Radioimmunotherapy: a specific treatment protocol for cancer by cytotoxic radioisotopes conjugated to antibodies.
Kawashima H
ScientificWorldJournal; 2014; 2014():492061. PubMed ID: 25379535
[TBL] [Abstract][Full Text] [Related]
9. Self-assembly of carbon nanotubes and antibodies on tumours for targeted amplified delivery.
Mulvey JJ; Villa CH; McDevitt MR; Escorcia FE; Casey E; Scheinberg DA
Nat Nanotechnol; 2013 Oct; 8(10):763-71. PubMed ID: 24077028
[TBL] [Abstract][Full Text] [Related]
10. Intraperitoneal injection is not always a suitable alternative to intravenous injection for radiotherapy.
Dou S; Smith M; Wang Y; Rusckowski M; Liu G
Cancer Biother Radiopharm; 2013 May; 28(4):335-42. PubMed ID: 23469942
[TBL] [Abstract][Full Text] [Related]
11. 90Y labeled phosphorodiamidate morpholino oligomer for pretargeting radiotherapy.
Liu G; Dou S; Liu Y; Wang Y; Rusckowski M; Hnatowich DJ
Bioconjug Chem; 2011 Dec; 22(12):2539-45. PubMed ID: 21985267
[TBL] [Abstract][Full Text] [Related]
12. Cancer radioimmunotherapy.
Sharkey RM; Goldenberg DM
Immunotherapy; 2011 Mar; 3(3):349-70. PubMed ID: 21395378
[TBL] [Abstract][Full Text] [Related]
13. Human islet cell MORF/cMORF pretargeting in a xenogeneic murine transplant model.
Liu G; Dou S; Cheng D; Leif J; Rusckowski M; Streeter PR; Shultz LD; Hnatowich DJ; Greiner DL
Mol Pharm; 2011 Jun; 8(3):767-73. PubMed ID: 21361360
[TBL] [Abstract][Full Text] [Related]
14. Engineering an antibody with picomolar affinity to DOTA chelates of multiple radionuclides for pretargeted radioimmunotherapy and imaging.
Orcutt KD; Slusarczyk AL; Cieslewicz M; Ruiz-Yi B; Bhushan KR; Frangioni JV; Wittrup KD
Nucl Med Biol; 2011 Feb; 38(2):223-33. PubMed ID: 21315278
[TBL] [Abstract][Full Text] [Related]
15. Unexpected side products in the conjugation of an amine-derivatized morpholino oligomer with p-isothiocyanate benzyl DTPA and their removal.
Liu G; Dou S; Liu Y; Liang M; Chen L; Cheng D; Greiner D; Rusckowski M; Hnatowich DJ
Nucl Med Biol; 2011 Feb; 38(2):159-63. PubMed ID: 21315270
[TBL] [Abstract][Full Text] [Related]
16. A preclinical 188Re tumor therapeutic investigation using MORF/cMORF pretargeting and an antiTAG-72 antibody CC49.
Liu G; Dou S; Baker S; Akalin A; Cheng D; Chen L; Rusckowski M; Hnatowich DJ
Cancer Biol Ther; 2010 Oct; 10(8):767-74. PubMed ID: 21099368
[TBL] [Abstract][Full Text] [Related]
17. Tumor pretargeting in mice using MORF conjugated CC49 antibody and radiolabeled complimentary cMORF effector.
Liu G; Dou S; Pretorius PH; Liu X; Chen L; Rusckowski M; Hnatowich DJ
Q J Nucl Med Mol Imaging; 2010 Jun; 54(3):333-40. PubMed ID: 20639818
[TBL] [Abstract][Full Text] [Related]
18. Pretargeted radioimmunotherapy for hematologic and other malignancies.
Walter RB; Press OW; Pagel JM
Cancer Biother Radiopharm; 2010 Apr; 25(2):125-42. PubMed ID: 20423225
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biodistribution of oligonucleotide-functionalized, tumor-targetable carbon nanotubes.
Villa CH; McDevitt MR; Escorcia FE; Rey DA; Bergkvist M; Batt CA; Scheinberg DA
Nano Lett; 2008 Dec; 8(12):4221-8. PubMed ID: 19367842
[TBL] [Abstract][Full Text] [Related]
20. Replacing 99mTc with 111In improves MORF/cMORF pretargeting by reducing intestinal accumulation.
Liu G; Cheng D; Dou S; Chen X; Liang M; Pretorius PH; Rusckowski M; Hnatowich DJ
Mol Imaging Biol; 2009; 11(5):303-7. PubMed ID: 19326173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
